General
Sickest coronavirus patients to be treated with arthritis drugs after study finds reduction in death rates
A study has found treating critically ill COVID-19 patients with Roche’s Actemra or Sanofi’s Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care.
Key points:
- The study involved 800 severely ill COVID-19 patients
- The UK Government said the drugs will be used to treat critically ill COVID-19 patients
- Results showed that on average, patients treated with Actemra or Kevzara recovered more swiftly
The findings, which have not yet been peer-reviewed, showed that the immunosuppressive drugs — Actemra, also known as tocilizumab, and Kevzara, also known as sarilumab — reduced death rates by 8.5 percentage points among patients hospitalised and severely ill with the pandemic…
-
Noosa News10 hours agoChef Sophie Phipps prepares to open restaurant at 30-acre Alsahwa Estate
-
General8 hours agoHopetoun on WA’s south coast will stop free camping, citing rubbish complaints
-
Business8 hours agoIs this the best ASX 200 share to buy for growth?
-
General17 hours agoThe Israel-Iran war: the moral failure of a policy of neutrality